Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 10/20 | 0.67 |
| ▸ | BLM | P54132 | 1/20 | 0.49 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.49 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4178067 | 0.83 | L3MBTL1 (0.59) | ARBLMSLC22A12 | |
| SCHEMBL4176579 | 0.81 | TAS2R14 (0.58) | ARTAS2R14SLC22A12 | |
| SCHEMBL24414726 | 0.80 | AR (1.00) | AR | |
| SCHEMBL5664793 | 0.78 | AR (0.55) | ARTAS2R14 | |
| SCHEMBL17658051 | 0.78 | BLM (0.63) | ARBLMTAS2R14SLC22A12 | |
| SCHEMBL5247689 | 0.76 | TAS2R14 (0.60) | ARBLMTAS2R14SLC22A12 | |
| SCHEMBL202386 | 0.76 | AR (0.52) | ARTAS2R14 | |
| SCHEMBL29415541 | 0.76 | AR (0.52) | ARTAS2R14 | |
| SCHEMBL202266 | 0.76 | AR (0.52) | ARBLMTAS2R14 | |
| SCHEMBL17664290 | 0.76 | AR (0.55) | ARBLMTAS2R14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090075989-A1 | NON-STEROIDAL PROGESTERONE RECEPTOR MODULATORS | BAYER SCHERING PHARMA AG (DE) | 2009-03-19 | — | — | US | disclosed |
| WO-2008077646-A1 | NON-STEROIDAL PROGESTERONE RECEPTOR MODULATORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090075989-A1 | NON-STEROIDAL PROGESTERONE RECEPTOR MODULATORS | NR5A1, CYP19A1, GPER1 | AR 145/4885BLM 3291/4885TAS2R14 2597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.